January 29, 2025 – Surge in Suboxone Plaintiffs
Nearly two years into the litigation, the volume of new Suboxone claims remains unexpectedly high. Our legal team continues to sign new plaintiffs at a pace similar to last year, far exceeding early expectations. This ongoing wave of new cases highlights the widespread impact of Suboxone-related dental injuries. Additionally, as more medical records are reviewed, it’s becoming increasingly clear that the extent of harm suffered by many individuals is even more severe than initially anticipated.
January 23, 2025 – A New Perspective on Failure-to-Warn Claims
An evolving legal argument in the Suboxone litigation takes a different approach to the failure-to-warn issue. Rather than focusing solely on whether patients would have avoided the medication entirely if properly informed, this claim underscores a lost opportunity for harm reduction. Had adequate warnings been provided, patients could have taken preventive measures—such as rinsing their mouths after use, increasing fluoride intake, or attending more frequent dental checkups—to minimize the risk of severe dental damage.
Pharmaceutical manufacturers often defend against failure-to-warn claims by arguing that patients would have taken the medication regardless, making the warning irrelevant. However, in this case, many Suboxone users might have continued their treatment but taken proactive steps to safeguard their dental health had they been properly informed. By failing to disclose these risks, Indivior denied patients the ability to protect themselves. This presents a unique angle in failure-to-warn litigation, differentiating it from more traditional cases.
January 10, 2025 – Indivior’s Perception of the Lawsuits
One key question remains: How does Indivior view the growing wave of litigation? The company has already faced legal scrutiny over Suboxone in the past, including criminal charges, yet continues to profit substantially from the drug.
It’s possible that Indivior believes juries will be less sympathetic toward plaintiffs with addiction histories. However, this assumption may be a critical miscalculation. Juries have historically responded to human suffering, and the powerful personal stories of Suboxone plaintiffs—many of whom followed medical guidance yet suffered severe dental damage—could resonate strongly. If Indivior does not offer fair settlement amounts reflective of these realities, it is likely these cases will proceed to trial rather than being resolved through a global settlement.
January 8, 2025 – New Suboxone Lawsuit Filed
A new lawsuit out of East Stroudsburg, Pennsylvania, details the devastating impact of Suboxone film on a plaintiff’s dental health. The individual, prescribed the medication for opioid dependency, developed severe and permanent dental damage, including cavities, cracked teeth, and gum disease.
Despite adhering to the prescribed dosage and maintaining proper oral hygiene, the plaintiff experienced rapid deterioration of their teeth, ultimately requiring fillings, root canals, and extractions. The complaint argues that Suboxone’s formulation—designed to optimize absorption—caused prolonged exposure to acidic conditions, leading to irreversible harm.
January 3, 2025 – Judge Partially Denies Motion to Dismiss
In a key ruling for plaintiffs, the MDL judge issued a decision that, while mixed, ultimately benefits those pursuing claims against Indivior. The ruling applied to a single case but is expected to set a precedent for similar claims moving forward.
The judge upheld the plaintiff’s pre-approval design defect claim, affirming that manufacturers had a duty to explore safer alternatives before FDA approval—such as Sublocade, an injectable form of buprenorphine. Additionally, the failure-to-warn claim was allowed to proceed, as Suboxone’s labeling did not warn of dental risks until 2022, leaving patients and healthcare providers unaware of the potential harm.
However, the court dismissed claims related to post-approval design modifications and narrowed the failure-to-warn argument to Indivior, the label-holder. While not a complete victory, this ruling reinforces the manufacturer’s responsibility to ensure its product’s safety and transparency about emerging risks.
January 5, 2024 – Answers About Suboxone Lawsuits
For those seeking more information, we continue to provide straightforward, honest answers about Suboxone lawsuits, including insight into potential settlement values and legal options.
